India · Delayed Price · Currency is INR Bal Pharma Statistics
Total Valuation
Bal Pharma has a market cap or net worth of INR 1.41 billion. The enterprise value is 2.98 billion.
| Market Cap | 1.41B |
| Enterprise Value | 2.98B |
Important Dates
The last earnings date was Wednesday, May 27, 2026.
| Earnings Date | May 27, 2026 |
| Ex-Dividend Date | Sep 18, 2025 |
Share Statistics
Bal Pharma has 15.92 million shares outstanding. The number of shares has increased by 0.35% in one year.
| Current Share Class | 15.92M |
| Shares Outstanding | 15.92M |
| Shares Change (YoY) | +0.35% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 52.16% |
| Owned by Institutions (%) | n/a |
| Float | 5.46M |
Valuation Ratios
The trailing PE ratio is 22.49.
| PE Ratio | 22.49 |
| Forward PE | n/a |
| PS Ratio | 0.45 |
| PB Ratio | 1.72 |
| P/TBV Ratio | 2.18 |
| P/FCF Ratio | 11.90 |
| P/OCF Ratio | 4.65 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.33, with an EV/FCF ratio of 25.04.
| EV / Earnings | 47.37 |
| EV / Sales | 0.96 |
| EV / EBITDA | 9.33 |
| EV / EBIT | 14.29 |
| EV / FCF | 25.04 |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 1.94.
| Current Ratio | 1.05 |
| Quick Ratio | 0.41 |
| Debt / Equity | 1.94 |
| Debt / EBITDA | 5.00 |
| Debt / FCF | 13.42 |
| Interest Coverage | 1.24 |
Financial Efficiency
Return on equity (ROE) is 7.92% and return on invested capital (ROIC) is 9.12%.
| Return on Equity (ROE) | 7.92% |
| Return on Assets (ROA) | 3.66% |
| Return on Invested Capital (ROIC) | 9.12% |
| Return on Capital Employed (ROCE) | 16.49% |
| Weighted Average Cost of Capital (WACC) | 7.67% |
| Revenue Per Employee | 3.16M |
| Profits Per Employee | 63,728 |
| Employee Count | 986 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 1.44 |
Taxes
| Income Tax | -3.86M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.64% in the last 52 weeks. The beta is 0.49, so Bal Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | -11.64% |
| 50-Day Moving Average | 81.51 |
| 200-Day Moving Average | 77.97 |
| Relative Strength Index (RSI) | 57.27 |
| Average Volume (20 Days) | 4,974 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bal Pharma had revenue of INR 3.12 billion and earned 62.84 million in profits. Earnings per share was 3.95.
| Revenue | 3.12B |
| Gross Profit | 1.54B |
| Operating Income | 208.24M |
| Pretax Income | 59.34M |
| Net Income | 62.84M |
| EBITDA | 319.03M |
| EBIT | 208.24M |
| Earnings Per Share (EPS) | 3.95 |
Balance Sheet
The company has 92.92 million in cash and 1.60 billion in debt, with a net cash position of -1.50 billion or -94.36 per share.
| Cash & Cash Equivalents | 92.92M |
| Total Debt | 1.60B |
| Net Cash | -1.50B |
| Net Cash Per Share | -94.36 |
| Equity (Book Value) | 822.52M |
| Book Value Per Share | 51.71 |
| Working Capital | 130.06M |
Cash Flow
In the last 12 months, operating cash flow was 304.43 million and capital expenditures -185.55 million, giving a free cash flow of 118.88 million.
| Operating Cash Flow | 304.43M |
| Capital Expenditures | -185.55M |
| Depreciation & Amortization | 110.79M |
| Net Borrowing | 91.36M |
| Free Cash Flow | 118.88M |
| FCF Per Share | 7.47 |
Margins
Gross margin is 49.32%, with operating and profit margins of 6.68% and 2.02%.
| Gross Margin | 49.32% |
| Operating Margin | 6.68% |
| Pretax Margin | 1.90% |
| Profit Margin | 2.02% |
| EBITDA Margin | 10.24% |
| EBIT Margin | 6.68% |
| FCF Margin | 3.81% |
Dividends & Yields
This stock pays an annual dividend of 1.20, which amounts to a dividend yield of 1.37%.
| Dividend Per Share | 1.20 |
| Dividend Yield | 1.37% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 30.40% |
| Buyback Yield | -0.35% |
| Shareholder Yield | 1.02% |
| Earnings Yield | 4.44% |
| FCF Yield | 8.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |